Skip to main content
RELIEF Therapeutics Holding AG logo

RELIEF Therapeutics Holding AG — Investor Relations & Filings

Ticker · RLF ISIN · CH1251125998 LEI · 506700IT19260EVD7916 SW Manufacturing
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country CH Switzerland
Listing SW RLF

About RELIEF Therapeutics Holding AG

https://www.relieftherapeutics.com/

RELIEF Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for specialty, rare, and ultra-rare diseases. The company's primary mission is to address significant unmet medical needs, particularly in areas such as rare metabolic disorders, by advancing treatment paradigms. It commercializes its products through a network of selected partners, aiming to deliver therapeutic solutions that significantly improve the condition and quality of life for patients. The portfolio includes a targeted clinical development pipeline and proprietary drug delivery platform technologies.

Recent filings

Filing Released Lang Actions
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
Regulatory Filings Classification · 88% confidence The document is an ad hoc announcement pursuant to Art. 53 LR (Swiss listing rule) disclosing a definitive channel partnership agreement. It is a corporate press release of inside information distributed via a regulatory news service (EQS News) and does not contain financial statements, voting results, share transactions, or management commentary. It does not fit any specific category such as earnings release, interim report, M&A, or capital change. As a general regulatory announcement, it falls into the fallback category of Regulatory Filings (RNS).
2026-05-12 English
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
Regulatory Filings
2026-04-30 English
MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update
Report Publication Announcement Classification · 90% confidence The document is an ad hoc announcement under Art. 53 LR on the SIX Swiss Exchange stating that MindMaze Therapeutics has published its 2025 Annual Report and providing a corporate update. It does not contain the full annual report or detailed financial statements; instead it directs investors to the published report on the company website. This matches the definition of a Report Publication Announcement (RPA).
2026-04-15 English
MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation
Regulatory Filings Classification · 75% confidence The document is a press release announcing clinical study (RWE) results, not a financial report, earnings release, regulatory form, or management presentation. It contains no financial performance metrics, no shareholder voting, no governance or capital change details, and is not an actual report publication notice. It is a miscellaneous corporate announcement, fitting the fallback category ‘Regulatory Filings (RNS)’.
2026-03-31 English
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
Regulatory Filings Classification · 95% confidence The document is a press release announcing that an external financial institution (Baader Bank) has initiated equity research coverage on MindMaze Therapeutics. This type of announcement does not fit into specific categories like financial reports, dividends, or management changes. As it is a general regulatory/corporate announcement that does not fall into the other defined categories, it is classified as a Regulatory Filing (RNS).
2026-03-19 English
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
Board/Management Information Classification · 100% confidence The document is an official ad hoc announcement regarding the appointment of a new CEO (Zach Henderson) and a new Chief Operating and Strategy Officer (Alexandre Capet) at MindMaze Therapeutics Holding SA. This falls directly under the category of board and management changes.
2026-03-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.